Host-directed vaccine therapies represent an innovative approach to vaccination that focuses on manipulating the host's immune system to improve its response to vaccines. Unlike traditional vaccines, which aim to directly target pathogens, host-directed therapies enhance the host's innate and adaptive immune responses, optimizing the body's ability to fight off infections. This strategy may involve boosting immune system signaling, promoting the activation of certain immune cells, or enhancing the function of the immune organs. By modulating the host’s immune environment, these therapies aim to create a more favorable setting for vaccine-induced protection, especially in individuals with weakened immune systems or those at high risk for infection. Host-directed therapies are particularly promising for diseases like tuberculosis, malaria, and HIV, where traditional vaccine strategies have had limited success. This emerging field holds the potential to revolutionize vaccine development, offering new tools for combating complex and persistent infectious diseases.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States